Abstract
Objective Report outcomes on patients with Multiple Sclerosis (MS) and related disorders with COVID-19 illness.
Methods From March 16 to April 30th, 2020, patients with MS or related disorders at NYU Langone MS Comprehensive Care Center (MSCC) were identified with laboratory-confirmed or suspected COVID-19. The diagnosis was established using a standardized questionnaire or by review of in-patient hospital records.
Results We identified 76 patients (55 with relapsing MS of which 9 had pediatric-onset;17 with progressive MS; and 4 with related disorders). 37 underwent PCR testing and were confirmed positive. Of the entire group, 64 (84%) patients were on disease-modifying therapy (DMT) including anti-CD20 therapies (n=34, 44.7%) and sphingosine 1-phosphate receptor modulators (n=10, 13.5%). The most common COVID-19 symptoms were fever and cough, but 21.1% of patients had neurologic symptom recrudescence preceding or coinciding with the infection. A total of 18 (23.7%) were hospitalized; 8 (10.5%) had COVID-19 critical illness or related death. Features more common among those hospitalized or with critical illness or death were older age, presence of comorbidities, progressive disease, and a non-ambulatory status. No DMT class was associated with an increased risk of hospitalization or fatal outcome.
Conclusions Most MS patients with COVID-19 do not require hospitalization despite being on DMTs. Factors associated with critical illness were similar to the general ‘at risk’ patient population. DMT use did not emerge as a predictor of poor COVID-19 outcome in this preliminary sample.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; Dr. Kister has served on advisory boards for Biogen and Genentech and received consulting fees from Roche and research support for investigator-initiated grants from Sanofi Genzyme, Biogen, EMD Serono, National MS Society, and Guthy Jackson Charitable Foundation. Dr. Sammarco receives consulting compensation from Biogen and Genentech. Dr. Krupp has received advisory board/consulting fees, travel and meal allowances, and/or research funding from Sanofi-Aventis, Biogen, Novartis, Gerson Lehman, EMD Serono, Allergan Inc., Tesaro Inc. She is also a non-compensated consultant and/or advisory board member with Novartis and Celgene; and receives royalties for use of the Fatigue Severity Scale by various biopharmaceutical entities. Dr. Zhovtis Ryerson received personal compensation for advisory board participation for Biogen and received research support from Biogen.No other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This was an unfunded study.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
I have full access to all of the data and have the right to publish any and all data separate and apart from any sponsor
